Phase II Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 04 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 12 Mar 2013 Actual initiation date changed from Mar 2011 to Jun 2011 as reported by ClinicalTrials.gov.
- 19 Feb 2013 Planned end date changed from 1 Feb 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.